TABLE 3.
Comparison of primary pharmacokinetic parameters of fosfomycin between dosing regimens and study days after two oral dosing regimensa
| Study day and dosing regimen (n) | Geometric mean (95% CI) |
||||||
|---|---|---|---|---|---|---|---|
| Cmax (μg/ml) | V/F (liters) | CL/Fb (liters/h) | t1/2 (h) | AUCc (μg · h/ml) | Cum Ae (mg) | CLR (liters/h) | |
| Day 1 | |||||||
| QOD (18) | 24 (20–28.8) | 172.3 (142.5–208.3) | 21.6 (20–23.2) | 5.6 (4.8–6.5) | 149.5 (130.6–171.2) | 1,063 (745.5–1,515.9) | 7.2 (5.5–9.3) |
| QD (18) | 23.6 (20.3–27.4) | 144.1 (119.8–173.3) | 22 (20.4–23.5) | 5.4 (4–7.3) | 148.64 (125.9–175.5) | 1,082.4 (832.5–1,407.3) | 7.9 (6.3–10) |
| Day 5 | |||||||
| QOD (18) | 24.7 (20.9–29.1) | 140.2 (114–172.5) | 21.4 (19.8–23) | 4.5 (4–5.2) | 152.8 (132.1–176.7) | 1,209.5 (820.4–1,783.3) | 7.7 (5.6–10.6) |
| QD (18) | 23.8 (20.9–27.2) | 146.7 (118.1–182.2) | 20.4 (18.9–22) | 5 (4.2–6) | 156.9 (137.4–179.1) | 1,159.3 (888.8–1,512.1) | 7.3 (6–8.9) |
a
QOD, every other day; QD, every day; CI, confidence interval.
b
CL/F data are arithmetic means.
c
AUC0–∞ on study day 1 and AUC0–24 on study day 5.